The addition of tezepelumab to standard treatment allowed half the adults with severe asthma to discontinue their use of oral corticosteroids (OCS) after 1 year, according to new data from nearly ...

Pattern of granulocyte colony stimulating growth factors (G-CSGF) usage in patients treated with sacituzumab govitecan: A real world multicenter study using the TriNetX database.. If you have the ...

The U.S. Food and Drug Administration has approved GSK's Nucala (mepolizumab) as an add-on maintenance treatment for adult patients with inadequately controlled chronic obstructive pulmonary ...

That said, Nucala and Dupixent will likely butt heads in the space following GSK’s launch, given that Dupixent's label covers a similar eosinophil-high patient population.

The FDA has approved Nucala (mepolizumab) for the add-on maintenance treatment of patients with inadequately controlled eosinophilic COPD.

FDA approves mepolizumab (Nucala; GSK) as the first monthly biologic for chronic obstructive pulmonary disease (COPD), significantly reducing exacerbations in patients with an eosinophilic phenotype.

Mepolizumab significantly reduced the annualized rate of moderate or severe exacerbations in COPD with an eosinophilic phenotype. Some 20% to 40% of COPD patients have elevated blood eosinophil ...

Recent research suggests that the biologic medications benralizumab and dupilumab can help treat emphysema. Learn more here.

SAN DIEGO — Patients with higher eosinophil counts experienced more cardiovascular disease, according to a poster presented at the 2025 American Academy of Allergy, Asthma & Immunology ...

Eohilia is an oral corticosteroid. Here’s how it treats eosinophilic esophagitis.

PHILADELPHIA — The current biologics for patients with COPD include anti-IL-5 therapies, dupilumab, tezepelumab and anti-IL-33 therapies, according to a presentation at the 2024 GOLD COPD ...

Immature granulocytes are white blood cells that have not yet matured. High levels can indicate conditions, such as leukemia. Learn more here.